Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Advancing precision oncology with large, real-world genomics and treatment outcomes data

Nature Medicine volume 28, pages 1544–1545 (2022)Cite this article

Subjects

Analysis of genomics data and medical records of over 40,000 patients with cancer identifies hundreds of mutations that are predictive of how well patients respond to specific cancer therapies. These predictive biomarkers could inform personalized treatment planning.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Gene–treatment interactions.

References

  1. Hodson, R. Precision medicine. Nature 537, S49 (2016). This outlook article highlights the need to translate the genomics profiles of patients into better treatment recommendations for precision medicine.

    Article  CAS  Google Scholar 

  2. Marquart, J., Chen, E. Y. & Prasad, V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 4, 1093–1098 (2018). This paper reports that only a minority of patients with cancer are eligible for genomics-informed therapy recommendations.

    Article  Google Scholar 

  3. Raponi, M., Winkler, H. & Dracopoli, N. C. KRAS mutations predict response to EGFR inhibitors. Curr. Opin. Pharmacol. 8, 413–418 (2008). This paper reports that KRAS mutations are associated with resistance to EGFR inhibitors in advanced non–small-cell lung cancer.

    Article  CAS  Google Scholar 

  4. Blonde, L., Khunti, K., Harris, S. B., Meizinger, C. & Skolnik, N. S. Interpretation and impact of real-world clinical data for the practicing clinician. Adv. Ther. 35, 1763–1774 (2018). This review discusses the advantages and limitations of real-world clinical data analysis.

    Article  Google Scholar 

  5. Ma, X. et al. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. Preprint at medRxiv https://doi.org/10.1101/2020.03.16.20037143 (2020). This paper reports the population characteristics of the cohort used in our study.

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Liu, R. et al. Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data. Nat. Med. https://doi.org/10.1038/s41591-022-01873-5 (2022).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Advancing precision oncology with large, real-world genomics and treatment outcomes data. Nat Med 28, 1544–1545 (2022). https://doi.org/10.1038/s41591-022-01904-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-01904-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer